
FDA issues US-wide recall of Mylan’s EpiPen
pharmafile | April 3, 2017 | News story | Medical Communications, Sales and Marketing | FDA, Mylan, epipen
After recent reports of around 80,000 defective EpiPen’s across Australia, New Zealand, Japan, Norway, Denmark, Finland and Ireland, the FDA has called for a voluntary nationwide recall of Mylan’s auto-injector in the US after news that products in that region are also failing to activate properly.
“The expanded voluntary recall is being initiated in the US and also will extend to additional markets in Europe, Asia, North and South America,” Mylan said.
The recall concerns a small number of devices across 13 lots, which have been manufactured with defective parts which prevent them for working correctly. All those with non-working products will be offered a replacement, but must contact Mylan directly. The FDA is also requesting that anyone affected reports it to its Medwatch website. Generic versions of the product are exempt from the recall.
All EpiPen models are manufactured at a single plant in St Louis, Missouri, so it is as yet unclear what caused the defective issue in the first place, or why this new wave of ineffective models was not included in the original recall in March.
Matt Fellows
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …






